Ramosetron

Ramosetron
Systematic (IUPAC) name
(1-methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]methanone
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration		 Intravenous
Pharmacokinetic data
Biological half-life 5.8 hours
Identifiers
CAS Number 132907-72-3 YesY
ATC code None
PubChem CID 108000
IUPHAR/BPS 2301
[3H]ramosetron: 2305
ChemSpider 97112 N
UNII 7ZRO0SC54Y N
ChEMBL CHEMBL1643895 N
Chemical data
Formula C17H17N3O
Molar mass 279.33 g/mol
 NYesY (what is this?)  (verify)

Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”.[2] In India it is marketed under the brand name of "IBset".


It is only licensed for use in Japan and selected Southeast Asian countries.　In Japan it is sold under the tradename Iribo (イリボー). [3] Elsewhere it is commonly sold under the tradename Nasea and in India as Nozia (300 mcg/ml Inj. & 100 mcg Tab.) [4]

References

  1. ↑ Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342.
  2. ↑ http://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html
  3. ↑ Summary in Japanese. Retrieved on September 4, 2012.
  4. ↑ Abridged prescribing information - Nasea (MIMS Philippines). Retrieved on June 13, 2008.


This article is issued from Wikipedia - version of the Saturday, January 30, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.